Literature DB >> 12187940

Pheochromocytomas and ganglioneuromas in the aging rats: morphological and immunohistochemical characterization.

Virgilio Pace1, Elias Perentes, Paul-Georg Germann.   

Abstract

We investigated, morphologically and immunohistochemically, 74 medullary adrenal tumors, including 64 pheochromocytomas (14 malignant and 50 benign), 9 ganglioneuromas, and 1 malignant schwannoma. The tumors were detected in 2-year-old Wistar and Sprague-Dawley rats from carcinogenicity studies. Morphologically, benign pheochromocytomas were characterized by monomorphic, small, basophilic cells with almost absence of mitoses. Malignant pheochromocytomas presented a low grade of pleomorphism, higher rate of mitoses, necrosis, infiltrative growth and in 1 case metastases in the lung. Ganglioneuromas were characterized by ganglion and neuron-like cells embedded in an eosinophilic matrix containing neurites, Schwann cells, and scant fibrovascular elements. All pheochromocytomas were strongly immunoreactive for tyrosine hydroxylase (TH), the rate-limiting enzyme in catecholamine synthesis. Subpopulations of chromaffin cells expressed chromogranin A (CGA) positivity. Matrix and Schwann cells were positive for S-100 and for glial fibrillary acidic protein (GFAP). In focal areas of the tumors, ganglion cells and axons were positive for neurofilament proteins (NFP) and synaptophysin. Ganglion cells exhibited peripherin and beta-tubulin. Proliferative activity of the tumors was assessed by immunostaining the endogenous cell proliferation associated-antigen Ki-67 and the proliferating cell nuclear antigen (PCNA). As expected, cell proliferation indices were much higher in malignant pheochromocytomas than in benign, yet ganglioneuromas remained immunonegative. Considering that Ki-67 antigen is more specific for cell proliferation, it should be regarded as marker of choice for supporting the differential diagnosis between benign and malignant pheochromocytomas.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12187940     DOI: 10.1080/01926230290105668

Source DB:  PubMed          Journal:  Toxicol Pathol        ISSN: 0192-6233            Impact factor:   1.902


  5 in total

Review 1.  Nonproliferative and Proliferative Lesions of the Rat and Mouse Endocrine System.

Authors:  Annamaria Brändli-Baiocco; Emmanuelle Balme; Marc Bruder; Sundeep Chandra; Juergen Hellmann; Mark J Hoenerhoff; Takahito Kambara; Christian Landes; Barbara Lenz; Mark Mense; Susanne Rittinghausen; Hiroshi Satoh; Frédéric Schorsch; Frank Seeliger; Takuji Tanaka; Minoru Tsuchitani; Zbigniew Wojcinski; Thomas J Rosol
Journal:  J Toxicol Pathol       Date:  2018-07-28       Impact factor: 1.628

2.  A comparative immunohistochemical study of spontaneous and chemically induced pheochromocytomas in B6C3F1 mice.

Authors:  Georgette D Hill; Virgilio Pace; Elke Persohn; Christina Bresser; Joseph K Haseman; Arthur S Tischler; Abraham Nyska
Journal:  Endocr Pathol       Date:  2003       Impact factor: 3.943

Review 3.  Methodological standardization for the pre-clinical evaluation of renal sympathetic denervation.

Authors:  Kenichi Sakakura; Elena Ladich; Elazer R Edelman; Peter Markham; James R L Stanley; John Keating; Frank D Kolodgie; Renu Virmani; Michael Joner
Journal:  JACC Cardiovasc Interv       Date:  2014-09-17       Impact factor: 11.195

4.  A xenograft and cell line model of SDH-deficient pheochromocytoma derived from Sdhb+/- rats.

Authors:  James F Powers; Brent Cochran; James D Baleja; Hadley D Sikes; Andrew D Pattison; Xue Zhang; Inna Lomakin; Annette Shepard-Barry; Karel Pacak; Sun Jin Moon; Troy F Langford; Kassi Taylor Stein; Richard W Tothill; Yingbin Ouyang; Arthur S Tischler
Journal:  Endocr Relat Cancer       Date:  2020-06       Impact factor: 5.678

5.  Differential expression of human telomerase catalytic subunit mRNA by in situ hybridization in pheochromocytomas.

Authors:  Zuojie Luo; Jianling Li; Yinfen Qin; Yan Ma; Xinghuan Liang; Jing Xian; Decheng Lu; Minyi Wei; Jack Y Yang; Mary Qu Yang; Zhiheng He
Journal:  Endocr Pathol       Date:  2006       Impact factor: 4.056

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.